– USA, TX – Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage fully-integrated biotherapeutics company, today announced the appointment of former Chair of the Audit Committee Pietro Bersani as Interim CEO, effective January 27, 2022, succeeding Dr. Maurizio Chiriva who departed from his roles as CEO and Chairman of the Board of Directors.
Effective January 27, 2022, Board member Michael Nagel was appointed as the new Chairman of the Board.
“I have been a member of the Kiromic Board of Directors since 2020, and I feel privileged to now lead this Company during this very pivotal year ahead. We have tremendous science, and a very important milestone to reach in the coming months,” said Interim CEO, Pietro Bersani. “The Kiromic leadership team is laser-focused on realizing our goal of first-in-human dosing and initiating clinical trials.”
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers.
From its heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Kiromic’s DIAMOND is where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to develop a live drug. The Company maintains offices in Houston, Texas.
For more information: https://kiromic.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.